0

Recombinant Vaccines Market Expected to Reach $24.7 Billion by 2031—Allied Market Research

 
2022
Recombinant Vaccines Market

Report Code : A17605

quote The factors that drive the growth of the recombinant vaccines market include increase in research and development activities for recombinant vaccines, rise in prevalence of infectious diseases and increase in rates of vaccinations globally. However, prolong period for introduction of new vaccines is expected to hinder the growth of this market. Conversely, the high growth potential in untapped emerging economies is expected to create lucrative opportunities for the market. quote

Onkar Sumant - Manager
Life Sciences at Allied Market Research

Get 20% Free Customization In This Report
Follow us on Social Media:       
 

According to a new report published by Allied Market Research, titled, “Recombinant Vaccines Market," The recombinant vaccines market was valued at $8.1 billion in 2021, and is estimated to reach $24.7 billion by 2031, growing at a CAGR of 11.4% from 2022 to 2031.

Recombinant vaccines rely on the capacity of one or multiple defined antigens to induce immunity against the pathogen, when administered in the presence of adjuvants or when expressed by plasmids or harmless bacterial/viral vectors. Recombinant protein vaccines permit the avoidance of several potential concerns raised by vaccines based on purified macromolecules, such as the risk of co-purification of undesired contaminants or reversal of the toxoids to their toxigenic forms, if considering diphtheria or tetanus toxoid vaccines, for example. Another fundamental issue overcome by this technology is the complexity involved in obtaining sufficient quantities of purified antigenic components. However, one of the main challenges in the development of these new strategies of immunization consists of designing vaccines that elicit the appropriate kind of immune response to confer immunity mainly to intracellular pathogens and especially to those that establish chronic, often lifelong infections. For this, the knowledge of the biology of highly conserved antigens involved in pathogenesis and of the immune mechanisms that should be elicited for protection must be obtained to rationally design vaccine strategies that can overcome the low protective immunity naturally generated by infection. There are a variety of expression systems for antigenic protein components, such as bacteria, yeast, mammalian cells and insect cells, in which the DNA encoding the antigenic determinant can be inserted and expressed. However, several factors must be taken into account before selecting the system for antigen expression. Most of the vaccines under investigation are based on highly purified recombinant proteins or subunits of pathogens. The classical example of recombinant protein vaccines currently in use in humans is the vaccine against hepatitis B. Hepatitis B virus (HBV) infection is a chronic liver disease occurring worldwide. HBV presents a marked tropism for human liver cells, partially due to a specific receptor that is expressed on the surface of infected cells.

The key drivers for the recombinant vaccines market size are increase in research and development activities for recombinant vaccines, rise in the prevalence of infectious diseases and increase in rates of vaccinations globally. Moreover, increasing incidence of zoonotic diseases, emerging technologies for developing vaccines and rise in the number of product approvals also helps in the growth of the recombinant vaccines market size. For instance, in June 2021, Merck and Sanofi received an approval for six-in-one pediatric combination vaccine in the U.S. However, prolong period for introduction of new vaccines is expected to hinder the growth of this market. Conversely, the high growth potential in untapped emerging economies is expected to create lucrative opportunities for the growth of the recombinant vaccines market share.

The COVID-19 pandemic had a positive impact on the recombinant vaccines industry owing to the increase in the research and development activities for development of effective vaccines. In addition, the increase in the advantages of vaccines also helped in the growth of the vaccines.

On the basis of indication, the market is classified into human papillomavirus, meningococcal and others. The human papillomavirus segment is projected to exhibit the fastest market growth during the forecast period, owing to increase in the prevalence of chronic diseases among the population, increase in the healthcare expenditure and increase in the adoption of recombinant vaccines technology.

On the basis of end user, the market is classified into pediatric and adult. The pediatric segment is anticipated to grow at the highest rate, owing to upsurge in number of patients of infectious diseases and increase in the number of vaccinations of the adult population globally and increase in the number of research and development activities for the recombinant vaccines used in the prevention of various diseases. Moreover, the rise in the prevalence of chronic diseases like hepatitis also helps in the growth of pediatric segment in the recombinant vaccines market share.

On the basis of distribution channel, the market is classified into hospitals and vaccination centers. The hospitals segment is further subsegment on the basis of type into private and public. The hospitals segment is anticipated to grow at the highest rate, owing to increase in the number of biotechnology companies that mainly focus on the development of recombinant vaccines, increase the research activities of vaccines development. Moreover, the rise in number of public hospitals with sufficient number of medical staff also contributes in the growth of the market.

On the basis of region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). In 2021, North America was the dominant region and is expected to remain dominant throughout the recombinant vaccines market forecast period, owing to high prevalence rate of chronic disease, increase in the number market players and surge in the vaccination rates in the region. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, owing to the presence of high populace countries such as India and China, which in turn increases the prevalence rate of infectious diseases, geriatric population, and the increasing number of product launch and other recombinant vaccines market trends adopted by the market players.

The key market players operating in this market include, AstraZeneca Plc., Dynavax Technologies Corporation, Emergent BioSolutions Inc., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novavax, Inc., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd.

KEY FINDINGS OF STUDY

  • By indication, the human papillomavirus segment accounted for major share of the recombinant vaccines industry in 2021.
  • By end user, the pediatric segment is anticipated to grow with the highest CAGR throughout the forecast period.
  • By distribution channel, the hospitals segment is anticipated to grow with the highest CAGR throughout the recombinant vaccines market analysis period.
  • By region, North America occupied major share of the recombinant vaccines market in 2021.
 

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975

pr-det-phone help@alliedmarketresearch.com

 

For Media Inquiries, Please Contact

Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at
media@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
 
 

First time buyer?
Check offers and discount on this report
To get this report

Click Here
 
 

quote Recombinant Vaccines Market by Indication (Human Papillomavirus, Meningococcal, Others), by End User (Pediatric, Adults), by Distribution Channel (Hospitals, Vaccination Centers): Global Opportunity Analysis and Industry Forecast, 2021-2031 quote

View Report
 
 

Avenue: Entire Library membership of Allied Market Research Reports at your disposal

  • Avenue is an innovative subscription-based online report database.
  • Avail an online access to the entire library of syndicated reports on more than 2,000 niche industries and company profiles on more than 12,000 firms across 11 domains.
  • A cost-effective model tailored for entrepreneurs, investors, and students & researchers at universities.
  • Request customizations, suggest new reports, and avail analyst support as per your requirements.
  • Get an access to the library of reports at any time from any device and anywhere.

 
 

WHY ALLIED MARKET RESEARCH?

INFLALLIBLE METHODOLOGY

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

ANALYST SUPPORT

For complete satisfaction

CUSTOMIZATION

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 

Featured Readings

 
rep-img

Published Date Jul 2024

Home Healthcare Market

Download Sample
rep-img

Published Date Jul 2024

Genotyping Market

Download Sample

Buy Full Version
"Recombinant Vaccines Market"
Purchase Enquiry

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of the scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save the time of readers